GE Healthcare teams up with J&J business to develop Alzheimer’s Dx
This article was originally published in Clinica
Executive Summary
GE Healthcare has entered a research agreement with Janssen Pharmaceutica, a Johnson & Johnson company, to identify a group of biomarkers that could be used to diagnose Alzheimer’s disease.